Opening Hook
In a country where Bollywood stars usually sell you pan masala, QMS MAS brought in Kapil Dev to pitch nebulizers and ortho belts. The gamble seems to have worked—QDevices alone clocked ₹10 crore in Q1, equal to all of last year’s sales (Q1FY26 concall). Meanwhile, consolidated revenue hit ₹46.5 crore, up 53% YoY, and PAT rose 31% YoY to ₹3.15 crore. Why does it matter? Because pharma promotions and patient service programs (PSPs) in India are a $70 billion global model waiting to scale. The only suspense—will regulations and execution help QMS convert this niche into a mainstream blockbuster?

At a Glance

• Revenue up 53% YoY – biggest Q1 in company history
• PAT rose to ₹3.15 cr – profits playing in the big league
• QDevices did ₹10 cr – Kapil Dev still hitting sixes at 66
• Saarathi added scale – PSPs now half the revenue story
• Debt-free growth so far – funding expansions without drama

Management’s Key Commentary

• “Q1 revenue ₹46.5 cr, our highest ever.”
  Translation: Growth graph finally beats Sensex memes.
• “QDevices crossed last year’s ₹10 cr in just Q1.”
  Translation: Kapil Dev as brand ambassador wasn’t just nostalgia marketing.
• “Saarathi delivered ₹4.6 cr revenue this quarter.”
  Translation: PSP acquisition isn’t window dressing—it’s working.
• “We are the only healthcare vendor on e-Grameen.”
  Translation: Rural India now buys nebulizers on government portals.
• “Services margins are double product margins.”
  Translation: Less hardware, more software = happier CFO.
• “Humrahi program empowers 1 lakh+ patients.”
  Translation: CSR meets revenue, pharma clients pay us for empathy.

Numbers Decoded

Analyst Questions

• Seven Islands: “Split between products & services?” Mgmt: “₹11 cr services, rest products.” Translation: SaaS dream still loading.
• Sapphire: “QDevices growth drivers?” Mgmt: “B2B orders, unique SKUs.” Translation: Wellness sells faster than medical devices.
• Plexus: “PSP opportunity?” Mgmt: “$70 bn globally, clean slate in India.” Translation: Market is wide open, we’re early movers.
• Norved: “Industry size?” Mgmt: “₹12,000 cr domestic, fragmented players.” Translation: We’re among the few crossing ₹100 cr turnover.
• AUM Capital: “Humrahi program revenue?” Mgmt: “6% of turnover, mostly fixed-fee.” Translation: Pharma pays steady retainer, not per-patient drama.